Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 31 min ago
Peer-reviewedCC BY 4.0JAMA Network Open

Bruton Tyrosine Kinase Inhibitor–Associated Pericardial Events by Agent and Generation

  • Vinicius De Sousa Barzon Serra1
  • Ramzi Ibrahim1
  • Julia Zanco1
  • Amjed Al Abdel1
  • Amal Youssef1
  • Dina Hauptschein2
  • Karam Albdour3
  • Luke Dreher1
  • Hema Narayanasamy1
  • Kwan Lee1
  • Balaji Tamarappoo1
  • J. Christopher Ray3
5 more authors
  • Talal Hilal2
  • Luis R. Scott1
  • Joerg Herrmann4
  • Chadi Ayoub1
  • Reza Arsanjani1
4 affiliations
  1. 1Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona
  2. 2Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona
  3. 3Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida
  4. 4Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota
Open at sourceDOICite

Abstract

This cross-sectional study investigates rates of incident pericardial effusion or cardiac tamponade in patients receiving Bruton tyrosine kinase inhibitors.

Related

  1. Aplastic Anaemia in a Chronic Lymphocytic Leukaemia Patient Treated With Acalabrutinib, a Bruton Tyrosine Kinase Inhibitor—Case Report
    Zachray Wei, Tamara Marconi, Lucy Tuck +1
    EJHaemPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Extranodal Organ Involvement in Chronic Lymphocytic Leukemia: Clinical Features and Outcomes With Bruton Tyrosine Kinase and BCL‐2 Inhibitors
    Finn J. Schulze, Evgenii Shumilov, Akhil Behringer +6
    Cancer MedicinePeer-reviewedCC BYFull textHuman geneticsDOAJ
  3. Bruton Tyrosine Kinase Inhibitors in Immune-Mediated Skin Diseases: Current Evidence and Future Directions
    Zihan Wang, Junchen He, Ting Zhang +6
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textGeneral medicineCrossrefEurope PMC
  4. Comparative Efficacy and Safety of Bruton Tyrosine Kinase and Spleen Tyrosine Kinase Inhibitors in Immune Thrombocytopenia: A Network Meta-Analysis of Clinical Trials.
    Ayah Abulehia, Raneen Bilal Alshareef, Shorouq Khateeb +7
    EJHaemPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  5. Bruton's tyrosine kinase inhibitors in primary immune thrombocytopenia: pathophysiology and clinical evidence.
    Tomás José González-López, Rick Kapur
    Blood vessels, thrombosis & hemostasisPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{serra2026bruton,
  title = {{Bruton Tyrosine Kinase Inhibitor–Associated Pericardial Events by Agent and Generation}},
  author = {Vinicius De Sousa Barzon Serra and Ramzi Ibrahim and Julia Zanco and Amjed Al Abdel and Amal Youssef and Dina Hauptschein and Karam Albdour and Luke Dreher and Hema Narayanasamy and Kwan Lee and Balaji Tamarappoo and J. Christopher Ray and Talal Hilal and Luis R. Scott and Joerg Herrmann and Chadi Ayoub and Reza Arsanjani},
  journal = {JAMA Network Open},
  year = {2026},
  month = nov,
  doi = {10.1001/jamanetworkopen.2026.42918},
  url = {https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2856346},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Bruton Tyrosine Kinase Inhibitor–Associated Pericardial Events by Agent and Generation
AU  - Vinicius De Sousa Barzon Serra
AU  - Ramzi Ibrahim
AU  - Julia Zanco
AU  - Amjed Al Abdel
AU  - Amal Youssef
AU  - Dina Hauptschein
AU  - Karam Albdour
AU  - Luke Dreher
AU  - Hema Narayanasamy
AU  - Kwan Lee
AU  - Balaji Tamarappoo
AU  - J. Christopher Ray
AU  - Talal Hilal
AU  - Luis R. Scott
AU  - Joerg Herrmann
AU  - Chadi Ayoub
AU  - Reza Arsanjani
PY  - 2026
DA  - 2026/11/09
JO  - JAMA Network Open
DO  - 10.1001/jamanetworkopen.2026.42918
UR  - https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2856346
AB  - This cross-sectional study investigates rates of incident pericardial effusion or cardiac tamponade in patients receiving Bruton tyrosine kinase inhibitors.
SN  - 2574-3805
ER  -